Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SCOPE-DMD

Financiado

Cerrado

Consortium for Products across Europe in Duchenne Muscular Dystrophy

This project builds on results from the TREAT-NMD and BIO-NMD European projects to develop a personalised-medicinal product through to market for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is an inheritable, childhood... ver más

31/05/2016

UNEW

21M€

Presupuesto del proyecto: 21M€

Líder del proyecto

UNIVERSITY OF NEWCASTLE UPON TYNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-05-31 No tenemos la información de la convocatoria

0% 28% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UNEW

0.00€ | Lider

Leiden University Medical Ce...

N.D. | Participante

Prosensa

2.36M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ANTES Accelerating Neuromuscular Treatment Selection 100K€ Cerrado

circRNA4DMD Circular RNA Therapeutics for Duchenne Muscular Dystrophy 3M€ Cerrado

SKIP-NMD A phase I IIa clinical trial in Duchenne muscular dystrophy... 8M€ Cerrado

QUESTFORMD Quantitative functional assessment of gene therapeutics for... 232K€ Cerrado

DMD2CURE Correction of duplications in the DMD gene by a CRISPR Cas9... 185K€ Cerrado

DYS_FUNCTION Novel use of exon skipping technology to study structure fun... 195K€ Cerrado

Líder del proyecto

UNIVERSITY OF NEWCASTLE UPON TYNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 21M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This project builds on results from the TREAT-NMD and BIO-NMD European projects to develop a personalised-medicinal product through to market for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is an inheritable, childhood rare disease that affects approximately 1 in 3,500 newborn boys. This rare disease is caused by mutations in the dystrophin gene, resulting in the absence or defect of the dystrophin protein. As a result, patients suffer from progressive loss of muscle strength, typically rendering them wheelchair-bound before the age of 12 and most patients die in early adulthood due to respiratory and cardiac failure. At present, there is no effective treatment for DMD. The goal of the SCOPE-DMD project is to develop a therapy that can restore the expression of a functional dystrophin protein in a targeted DMD patient sub-population. This will be achieved using RNA-based technology, specifically antisense oligonucleotides (AON) inducing exon skipping. The clinical heterogeneity and disease complexity in rare diseases present a major challenge to properly observe statistically and clinically meaningful treatment effects. Innovative clinical study designs and novel outcome measures are required to reduce development timelines. Based on extensive experience from classical clinical trials of two other AONs in DMD patients, the consortium has designed a highly innovative development plan, including an innovative clinical trial design that if successful, could be applied to future clinical trials in DMD and other rare diseases. Also novel biomarkers and functional outcome measures will be incorporated in additional to more established ones. Multiple layers of expertise and scientific knowledge come together in this SCOPE-DMD project consortium to launch an innovative drug product but also to provide a regulatory and pathway-to-market precedence in order to benefit future patients with rare disorders getting earlier access to treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores